AstraZeneca’s Chief Executive Officer, Pascal Soriot, has cautioned that trade tariffs are ineffective in managing the pharmaceutical sector, as drug manufacturers express concern over potential U.S. duties.
AstraZeneca plans £2bn investment in Beijing despite ongoing China investigation
AstraZeneca has announced plans to invest £2 billion in Beijing, just months after Chinese authorities detained the head of its China division over alleged illegal activities.
AstraZeneca experiences a £2.8 billion reduction in its value due to concerns over expenses.
Shares of AstraZeneca PLC (LSE: AZN) dropped by 1.8%, leading to a £2.8 billion decrease in the company’s market value. This decline was primarily due to ongoing concerns about the
AstraZeneca (LON:AZN) set to acquire a Chinese pharmaceutical company in a multi-billion dollar agreement.
AstraZeneca PLC (LON: AZN) is poised to complete a substantial acquisition, purchasing Gracell Biotechnologies, a Chinese firm renowned for its innovative therapies targeting cancer and autoimmune diseases, in a deal
AstraZeneca enhances its earnings amid the emergence of legal proceedings related to vaccines.
AstraZeneca surpassed profitability expectations as it disclosed its third-quarter earnings, even as it confronts a significant legal challenge alleging that the effectiveness of its vaccines was greatly exaggerated.
AstraZeneca (LON:AZN) reaches a monthly peak due to positive outcomes from a breast cancer medication trial.
Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
AstraZeneca (LON:AZN) and Alexion collaborate with the FDA to broaden the US label for Ultomiris.
AstraZeneca PLC (LON: AZN) announced that the US Food and Drug Administration (FDA) has requested a risk assessment and mitigation strategy in response to a proposal to broaden the application
AstraZeneca subsidiary finalizes a US$1bn deal with Pfizer for rare diseases.
AstraZeneca has reported a stronger-than-anticipated performance in the second quarter, with robust sales from its leading cancer drugs offsetting the decline in Covid vaccine sales.